Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1PRETEXT I Hepatoblastoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms 1Neoplasm Metastasis 1Endometrial Adenocarcinoma 1Desmoplastic Small Round Cell Tumor 1Brain Neoplasms 1Advanced Rare Tumours 1Advanced Cancer 1Adult Solid Neoplasm 1

Interventions

Cyclophosphamide 7X-Rays 5Vincristine 5Phantoms, Imaging 5Magnetic Resonance Spectroscopy 5Vinorelbine 4Specimen Handling 4Nuclear Medicine Department, Hospital 4Irinotecan 4Dactinomycin 4Biopsy 4Radiotherapy 3Radiation 3Etoposide 3ulixertinib 2tipifarnib 2selpercatinib 2palbociclib 2larotrectinib 2ivosidenib 2etoposide phosphate 2ensartinib 2Temozolomide 2Sirolimus 2Ifosfamide 2Filgrastim 2Doxorubicin 2Dexrazoxane 2temsirolimus 1tazemetostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Rhabdomyosarcoma × temsirolimus × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡